Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Epclusa Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Epclusa (sofosbuvir/velpatasvir) Prior Authorization Coverage

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for Epclusa in adults with chronic hepatitis C virus genotype 1 through 6 infection, including patients with compensated or decompensated cirrhosis and certain previously treated patients.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyEpclusa (sofosbuvir/velpatasvir) Prior Authorization Coverage
    Policy CodePolicy N/A
    Change TypeRetired / Archived
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing the HCV genotype, patient age, fibrosis score, cirrhosis status, treatment history, specialist involvement, and planned regimen and duration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1–6Covered HCV genotypes
    ≥18Minimum age
    ≥2Fibrosis threshold
    12 weeksStandard duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    24 weeks
    Extended duration
    ArchivedDisposition

    Coverage Criteria

    Initial therapy: no cirrhosis or compensated cirrhosis

    Approve Epclusa for 12 weeks when all criteria are met.

    Required criteria

    • Eligibility requirements

      • Age: Patient is at least 18 years of age.≥18 years
      • Specialist involvement: Epclusa is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
      • Fibrosis: Patient has a fibrosis score of at least 2.≥2
      • Prior Epclusa treatment: Patient has not been previously treated with Epclusa.
      • Cirrhosis status: Patient does not have cirrhosis or has compensated cirrhosis, Child-Pugh A.Child-Pugh A if cirrhosis is present

    Initial therapy: decompensated cirrhosis

    Approve Epclusa for the specified duration when all criteria are met.

    Required criteria

    • Eligibility requirements

      • Age: Patient is at least 18 years of age.≥18 years
      • Specialist involvement: Epclusa is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
      • Fibrosis: Patient has a fibrosis score of at least 2.≥2

    Previously treated decompensated cirrhosis

    Approve Epclusa for 24 weeks when all criteria are met.

    Required criteria

    • Eligibility requirements

      • Age: Patient is at least 18 years of age.≥18 years
      • Specialist involvement: Epclusa is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
      • Fibrosis: Patient has a fibrosis score of at least 2.≥2

    Non-approval conditions: Epclusa is not approved for hepatitis C virus infection of any genotype as stated in the policy’s non-approval section, use in combination with any other direct-acting antiviral except ribavirin, patients with a life expectancy of less than 12 months due to non-liver-related comorbidities, or pediatric patients younger than 18 years.

    Coding and Thresholds

    Fibrosis score
    Required fibrosis score≥ 2

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Documentation Required

    Prior authorization documentation must establish the applicable Epclusa indication and treatment plan. Submit the patient’s HCV genotype (1–6), age, fibrosis score, cirrhosis status and Child-Pugh class, prior Epclusa/Vosevi treatment history, prescriber or specialist consultation, requested duration, and—when applicable—ribavirin use.

    • Patient is 18 years of age or older.
    • HCV genotype is 1, 2, 3, 4, 5, or 6.
    • Fibrosis score is ≥ 2.
    • For no cirrhosis or compensated cirrhosis, document no cirrhosis or Child-Pugh A cirrhosis; for decompensated disease, document Child-Pugh B or C cirrhosis.
    • Document whether the patient has previously received Epclusa or Vosevi, as applicable to the requested indication.
    • Epclusa is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • For patients previously treated with Epclusa or Vosevi who have decompensated cirrhosis, document the 24-week request and concurrent ribavirin prescription.

    Clinical Background

    Epclusa is a fixed-dose combination of velpatasvir, an HCV NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor. It is used to treat chronic hepatitis C virus infection caused by genotypes 1 through 6 in adults. The regimen is used alone for patients without cirrhosis or with compensated cirrhosis and with ribavirin for patients with decompensated cirrhosis.

    Definitions

    Child-Pugh classification
    Compensated cirrhosisChild-Pugh A
    Decompensated cirrhosisChild-Pugh B or C
    No cirrhosisEligible under the no-cirrhosis pathway

    Initial Therapy Criteria

    Initial therapy: compensated or no cirrhosis

    Approve Epclusa for 12 weeks when all criteria are met.

    Required criteria: Adult patient has chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection, a fibrosis score of at least 2, no prior Epclusa treatment, and no cirrhosis or compensated cirrhosis (Child-Pugh A). Epclusa is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.12 weeks

    Initial therapy: decompensated cirrhosis

    Approve Epclusa for 12 or 24 weeks based on ribavirin eligibility when all criteria are met.

    Required criteria

    • Ribavirin eligibility and duration

      • Ribavirin eligible:

    Continuation Therapy

    Patient already started on Epclusa

    Patients already started on Epclusa may be approved to complete an approved course.

    Continuation of an approved course: Patient has been started on Epclusa for an indication or condition addressed as an approval under the FDA-approved indications or other uses with supportive evidence, and the requested quantity completes the applicable approved course duration.Remaining portion of approved course

    For example, a 12-week course with 3 weeks already received may be approved for the remaining 9 weeks.

    Step Therapy Requirements

    StepRequirement
    1For the no-cirrhosis or compensated-cirrhosis pathway, the patient must not have been previously treated with Epclusa.
    StepRequirement
    2For decompensated cirrhosis pathways, treatment history with Epclusa or Vosevi must match the applicable pathway: no prior Epclusa or Vosevi treatment for initial therapy, or prior treatment with Epclusa or Vosevi for previously treated patients.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyEpclusa (sofosbuvir/velpatasvir) Prior Authorization Coverage
    Policy CodePolicy N/A
    Change TypeRetired / Archived
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing the HCV genotype, patient age, fibrosis score, cirrhosis status, treatment history, specialist involvement, and planned regimen and duration.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ThresholdsProvider Actions and AuthorizationClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation TherapyStep Therapy Requirements
    Prior treatment: Patient has not been previously treated with Epclusa or Vosevi.
  1. Cirrhosis status: Patient has decompensated cirrhosis, Child-Pugh B or C.Child-Pugh B or C
  2. Ribavirin eligibility and duration

    • Ribavirin eligible: Patient is ribavirin-eligible according to the prescribing physician and Epclusa is prescribed in combination with ribavirin.12 weeks

      Approve for 12 weeks.

    • Ribavirin ineligible: Patient is ribavirin-ineligible according to the prescribing physician.24 weeks

      Approve Epclusa for 24 weeks.

  3. Prior treatment: Patient has been previously treated with Epclusa or Vosevi, with a null response, partial response, or relapse.
  4. Cirrhosis status: Patient has decompensated cirrhosis, Child-Pugh B or C.Child-Pugh B or C
  5. Combination therapy: Epclusa will be prescribed in combination with ribavirin.
  6. Denial Risk

    Explicit Non-Approval Conditions

    Do not approve Epclusa when the request falls within an expressly excluded population or treatment combination.

    • HCV of a genotype outside 1, 2, 3, 4, 5, or 6.
    • Combination with any other direct-acting antivirals (DAAs), except ribavirin.
    • Life expectancy of less than 12 months due to non-liver-related comorbidities.
    • Pediatric patient younger than 18 years of age.
    Denial Risk

    Clinical Criteria Not Met

    Authorization is at risk for denial when the applicable clinical criteria are not met or are not adequately documented. The requested indication must match the patient’s cirrhosis status and treatment history.

    • Fibrosis score is less than 2 or is not documented.
    • Patient is younger than 18 years of age.
    • Epclusa is not prescribed by or in consultation with a qualifying specialist.
    • For no cirrhosis or compensated cirrhosis requests, the patient has decompensated cirrhosis or otherwise fails the required cirrhosis criterion.
    • For decompensated cirrhosis requests, Child-Pugh B or C status is not established.
    • For treatment-naive requests, the patient was previously treated with Epclusa when prior Epclusa treatment is exclusionary.
    • For the supportive-evidence request involving decompensated cirrhosis, prior null response, partial response, or relapse, prior Epclusa or Vosevi treatment is not documented or ribavirin is not prescribed.
    • The requested duration or regimen does not correspond to the applicable indication, including the 24-week regimen with ribavirin for previously treated patients with decompensated cirrhosis.
    Patient is ribavirin-eligible according to the prescribing physician and Epclusa is prescribed in combination with ribavirin.
    12 weeks

    Approve for 12 weeks.

  7. Ribavirin ineligible: Patient is ribavirin-ineligible according to the prescribing physician.24 weeks

    Approve Epclusa for 24 weeks.

  8. Previously treated patient

    Approve Epclusa for 24 weeks when all criteria are met.

    Required criteria: Adult patient has chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection, a fibrosis score of at least 2, decompensated cirrhosis (Child-Pugh B or C), and prior treatment with Epclusa or Vosevi resulting in a null response, partial response, or relapse. The regimen includes ribavirin.24 weeks